This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Medtronic (MDT) Gets FDA Nod to Study Intrepid TMVR System
by Zacks Equity Research
The FDA clearance is expected to boost Medtronic's (MDT) structural heart business.
Haemonetics Grows on Strong Plasma, Hemostasis Management
by Zacks Equity Research
Haemonetics (HAE) is gaining traction from a steady progress in Plasma franchise.
Here's Why You Should Hold Zimmer Biomet (ZBH) Stock for Now
by Zacks Equity Research
Investor confidence continues to be high in Zimmer Biomet (ZBH), thanks to solid prospects.
Here's Why You Should Hold GNC Holdings (GNC) Stock for Now
by Zacks Equity Research
Investor confidence continues to be high in GNC Holdings (GNC), thanks to solid prospects.
Illumina (ILMN) Gains on Product Pipeline, Global Footprint
by Zacks Equity Research
Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).
Medtronic's MiniMed 670G Shows Favorable Outcome in Europe
by Zacks Equity Research
Medtronic's (MDT) MiniMed 670G system boasts a special feature of SmartGuard Auto Mode that improves Time in Range.
QIAGEN (QGEN) Hurt by Low QuantiFERON-TB Sales & FX Headwind
by Zacks Equity Research
Poor QuantiFERON-TB sales in Americas and an unfavourable currency translation affect QIAGEN's (QGEN) overall performance.
Align Technology Inks Distribution Deal With Zimmer Biomet
by Zacks Equity Research
This deal indicates Align Technology's (ALGN) commitment to strengthen its portfolio of iTero scanner and services.
Tandem Diabetes Posts Positive Data on t:slim X2 With Basal-IQ
by Zacks Equity Research
Of late, Tandem Diabetes (TNDM) is investing in several developmental projects pertaining to the t:slim X2 insulin pump.
Here's Why You Should Retain Globus Medical (GMED) Stock Now
by Zacks Equity Research
Investor confidence continues to be high in Globus Medical (GMED), thanks to solid prospects.
Intersect ENT Rides on Innovation Amid Pricing Concerns
by Zacks Equity Research
The SINUVA business line of Intersect ENT (XENT) makes a quick and remarkable progress with market access and field force balance.
Medtronic Collaborates With Novo Nordisk for Diabetes Care
by Zacks Equity Research
This collaboration is expected to boost Medtronic's (MDT) diabetes management portfolio.
Medtronic's (MDT) IN.PACT AV Access Study Results Bode Well
by Zacks Equity Research
The results of the study will prove to be a major stride for Medtronic (MDT) to treat patient suffering from renal diseases.
Haemonetics (HAE) Down 0.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Haemonetics (HAE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Invest in Haemonetics (HAE) Right Now
by Zacks Equity Research
Haemonetics (HAE) has been enjoying investors' rising optimism, owing to solid prospects.
LabCorp's Covance Launches Laboratory Data Management Service
by Zacks Equity Research
LabCorp (LH) expands service portfolio through Covance's data management portal.
New Strong Buy Stocks for August 29th
by Tirthankar Chakraborty
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday
AtriCure Gains Expanded Labeling for Atriclip, Braces LAA Arm
by Zacks Equity Research
AtriCure's (ATRC) AtriClip devices are currently the most widely implanted left atrial appendage management devices globally.
Allscripts Inks Deal With Apple for Electronic Health Record
by Zacks Equity Research
Allscripts (MDRX) is working toward providing compact health records.
Haemonetics Rides on Strong Plasma and Global Expansion
by Zacks Equity Research
Continued momentum in new business generation and geographical expansion contributes to the results of Haemonetics (HAE).
Omnicell's Autonomous Pharmacy to Boost Medication Management
by Zacks Equity Research
Omnicell (OMCL) aims to combine technology and innovation to enable pharmacists to expand their outreach to patients and improve services.
EYE vs. HAE: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EYE vs. HAE: Which Stock Is the Better Value Option?
Baxter's PrisMax Adopted by Hamilton Health Care System
by Zacks Equity Research
Baxter's (BAX) PrisMax System first adopted by Hamilton Health, which in turn is expected to enhance patient care.
Myriad Genetics (MYGN) Q4 Earnings Lag Estimates, Revenues Up
by Zacks Equity Research
Myriad Genetics' (MYGN) overall Q4 performance is impressive, excepting weak sales at a few segments.
Here's Why You Should Invest in HMS Holdings (HMSY) Stock Now
by Zacks Equity Research
HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services as well as robust margins.